Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study

Table 4 Multivariate analysis of the predictive value of cumulative smoking dose on survival outcomes in patients with EGFR mutation receiving EGFR-TKIs

variable	category	PFS to EGFR-TKI		p-value	OS	95% CI	p-value
variable	category	HR	95% CI	p-value	HR	95% CI	p-value
Smoking history	ever- smokers vs never smoker	1.89	1.27–2.81	0.002	1.52	0.87–2.64	0.13
Smoking dosage	never smoker	1.00			1.00
	≤10 PY	0.81	0.43–1.50	0.49	0.83	0.32–2.14	0.68
	11~ 30 PY	4.00	1.95–8.23	< 0.001	1.52	0.79–2.96	0.21
	> 30 PY	16.2	6.37–61.6	< 0.001	3.98	1.84–8.28	< 0.001

Adjusted by Age, PS, Sex, clinical stage and time of targeted therapy
Abbreviations: PFS progression-free survival, OS overall survival, Ref. reference, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, PS performance status, HR hazard ratio, 95% CI 95% confidence interval, PY pack-years

ISSN: 1471-2407